Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gabriel Dan Duda, D.M.D., Ph.D.

Profile Picture

University of Medicine Iasi, Romania, Iasi, RomaniaDMD09/1993Dentistry
Tohoku University Medical School, Sendai, JapanPhD03/2001GI Surgery
Harvard Medical School, Boston, MAPostdoctoral Fellow05/2004Tumor biology
1997 - 2001
Monbusho Graduate Research Fellowship
Young Investigator Award, IAP
Scholar-in-Training Award, AACR
Travel Grant Award, Japanese Surgical Society
2002 - 2005
Postdoctoral Fellowship, Cancer Research Institute
Travel Grant Award
2005 - 2007
Career Development Award for Cancer Research in Angiogenesis, AACR
Scholarship, European Commission Marie Curie Actions Programme
2008 - 2009
Ira J. Spiro Translational Research Award
Early Career Oncologists / Scientists (ECOS) Award EORTC-NCI-ASCO
2010 - 2011
Ira J. Spiro Translational Research Award
2011 - 2012
Ira J. Spiro Translational Research Award
Capussotti Award, IASGO
Keio University Lecture
2014 - 2016
Fellow, Andrew L. Warshaw, M.D., Institute for Pancreatic Cancer
Keynote Speaker, Wolfsberg/ ESTRO Radiation Biology Meeting
Tohoku Medical Society Lecture
Keynote Lecture, Neuroononcology Group (NOA) Winterschool Freiburg, Germany
Honoree of the One Hundred
Heroes of Hope Award, Granara-Skerry Trust
State-of-the-art Lecture, IASGO World Congress, Korea
Plenary Lecture, Hong Kong International Oncology Forum
2017 - 2019
Partners HealthCare Innovator Awards
Keio Medical Society Lecture
IASGO Achievement Award
Excellence Award on the occasion of the 100th Anniversary of Unification of the Romanian State
Induction into the AIMBE College of Fellows – Class of 2020
2020 Excellence Award – World Ambassador of Romanian Medicine
Doctor Honoris Causa University of Medicine Iasi, Romania
2021 AAAS Fellow
Erudite Scholar-in-Residence, KSHEC, India
Elected as Foreign Member, Academy of Europe

Education and Academic Appointments

Dr. Duda obtained a DMD from the University of Medicine Iasi, Romania, in 1993 and then earned a Ph.D. in Medical Sciences (Gastrointestinal Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan, in 2001. After graduation, he pursued postdoctoral training with Professor Rakesh K. Jain in the Steele Laboratories for Tumor Biology, Department of Radiation Oncology, MGH, and Harvard Medical School in Boston for 3 years. In 2004, Dr. Duda became a Junior Faculty member at Harvard (Instructor). He then became a Full Investigator at MGH Research Institute in 2016 and a Professor of Radiation Oncology in 2023. In 2016, Dr. Duda was appointed Director of Translational Research in Gastrointestinal Radiation Oncology at MGH. In 2021, he received the honorary degree "Doctor Honoris Causa" from the University of Medicine Iasi, Romania, his Alma Mater.

Research Goals of the Duda Lab

Over the last decade and a half, Dr. Duda has built a productive Liver Cancer Research Program at Steele Laboratories for Tumor Biology. The translational goal of this program is to increase the durability of response to the most effective available therapies. The approach is to identify new cellular and molecular mechanisms of local and metastatic tumor progression and treatment resistance and validate them as new targets for combination therapies for these cancers.

His group studies the activity of agents targeting the tumor microenvironment (antiangiogenic or antifibrotic agents) or targeting the cancer cells (radiotherapy, chemotherapy, targeted agents) combined with immunotherapy approaches. To this end, they developed preclinical models that reproduce hallmarks of human cancers, including genetically engineered models of primary hepatocellular carcinoma and cholangiocarcinoma, and metastatic pancreatic, breast, and prostate carcinomas. In parallel, they are conducting correlative studies of biomarkers of response to the same approaches in clinical trials in cancer patients in a CLIA-certified environment. Dr. Duda's research is supported by multiple grants from the National Cancer Institute (NCI), by Department of Defense (DoD) awards, and by sponsored agreements with Industry partners.

Track Record and Service

Dr. Duda has authored 261 publications so far. Of these, 162 are original reports, including basic research published in Nature, Nature Medicine, Nature Biotechnology, Nature Genetics, Nature Communications, Cell, Cancer Cell, Science Translational Medicine, JNCI, Gut, and Hepatology, and clinical reports published in Journal of Clinical Oncology, npj Precision Oncology, and JAMA Oncology. Over the last two decades, he has been invited to present our results at over 250 local, national, and international meetings, including in Grand Rounds (Harvard, Mayo Clinic, Yale, Fred Hutchinson Cancer Center), Plenary and State-of-the-art Talks (AACR, ISSCR, IASGO, IAP), and Keynote Lectures. Dr. Duda has received multiple awards for his research, including from the AACR, Cancer Research Institute (CRI), IASGO, and MGH. He became an Honorary Member of the Academy of Medical Sciences of Romania in 2012, was inducted into the College of Fellows of the American Institute for Medical and Biomedical Engineering (AIMBE) in 2020, and was elected as a 2021 American Association for the Advancement of Science (AAAS) Fellow in 2022. He was elected as a Foreign Member of the Academy of Europe (Academia Europaea) in 2023.

Dr. Duda has been a chartered or ad-hoc Member and the Chair or co-Chair of multiple expert panels. These included US NCI study sections (currently Chair of the Cancer Diagnostics and Treatments Study Section since 2022), American Cancer Society (ACS) Tumor Biology Group, US Department of Defense (DOD) Peer Reviewed Cancer Program, and Belgium FWO (Chair of the Med4 panel 2018-2020). He is a Founding Editor of Surgery, Gastroenterology and Oncology and Senior Associate Editor of the International Journal of Radiation Oncology*Biology*Physics. He is an Editorial Board member for several other journals, including Clinical & Translational Radiation Oncology, Journal of Hepatocellular Carcinoma, Digestive Surgery, and Cancers. Since 2015, he has been serving as the Secretary-General of the IASGO. In addition, Dr. Duda was a member of the American Association for the Study of Liver Diseases (AASLD) Liver Fibrosis Special Interest Group, a member of the NCI Hepatobiliary Task Force for Immuno-Oncology Biomarkers, and a member of the SWOG Cancer Research Network, GI and Translational Medicine GI Committees. Dr. Duda will chair the Forbeck Forum on “The Biology and Treatment of Hepatocellular Carcinoma” in 2023 and the "Boston Angiogenesis Meeting" in 2024.


Dr. Duda teaches tumor biology and translational oncology through the daily supervision of postdoctoral research fellows and graduate and undergraduate students (50+ in the last 15 years). As a passionate supporter of IASGO's mission to globalize the best medical practice and knowledge worldwide, he has been coordinating, teaching, and directing Postgraduate Courses in 29 countries in Asia, Europe, Africa, and the Americas since 2013. He has taught nationally in ASTRO and RTOG translational meetings for residents and clinicians and locally in the MIT-HMS Health, Science, and Technology Program since 2005. In addition, he has been coordinating a research exchange student program with the University of Muenster, Germany, since 2015 and has been directing the Annual Course titled "Methods in Biomedical Engineering, Tumor Biology, and Immunology" at MGH since 2004. He edited the "IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases", published by Nature-Springer in 2022.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P01CA261669 (HONG, THEODORE S) Sep 21, 2021 - Aug 31, 2026
    Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy.
    Role: Core B Director
  2. W81XWH-21-1-0738 (DUDA, DAN G) Aug 1, 2021 - Jul 31, 2024
    Mechanisms Mediating the Immune Responses after Proton versus Photon Radiotherapy in IDH Mutant Liver Cancer
    Role Description: The aim of this grant is to use liver cancer models to validate the increased biological effects of proton therapy in vivo and link the increased efficacy with to a clinically testable tumor genotype and facilitate the design of combinations with immunotherapy.
    Role: Principal Investigator
  3. R03CA256764 (FERRONE, SOLDANO) Jul 8, 2021 - Jun 30, 2023
    Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC
    Role: Multiple Principal Investigator
  4. R01CA247441 (MUNN, LANCE L) Jul 1, 2021 - Jun 30, 2026
    Vascularized tumor explants for drug testing
    Role: Multiple Principal Investigator
  5. R01CA260857 (KUMAR, ANAND T.N.) Apr 1, 2021 - Jun 30, 2026
    Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
    Role: Multiple Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Duda's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (587)
Co-Authors (173)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.